Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 6, 1997, Pages 797-802

  Klugman, K P ^a   Capper, T ^a  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; QUINOLINES; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 0031468027     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.6.797     Document Type: Article

References (29)

1. Klugman, K. P., Goldstein, F., Kohno, S. & Baquero, F. (1997). Role of fourth generation cephalosporins in the treatment of penicillin-resistant streptococcal infections. Clinical Microbiology and Infection 3, Suppl. 1, S48-60.
2. Pallares, R., Gudiol, F., Linares, J., Ariza, J., Rufi, G., Murgui, L. et al. (1987). Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New England Journal of Medicine 317, 18-22.
3. Friedland, I. R. & Klugman, K. P. (1992). Antibiotic-resistant pneumococcal disease in South African children. American Journal of Diseases of Childhood 146, 920-3.
4. Klugman, K. P. (1994). Management of antibiotic-resistant pneumococcal infections. Journal of Antimicrobial Chemotherapy 34, 191-3.
5. Friedland, I. R. (1995). Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Paediatric Infectious Diseases Journal 14, 885-90.
6. Pallares, R., Linares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F. et al. (1995). Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine 333, 474-80.
7. Gomez, J., Banos, V., Ruiz Gomez, J., Herrero, F., Nunez, M. L., Canteras, M., et al. (1995). Clinical significance of pneumococcal bacteraemias in a general hospital: a prospective study 1988-1993. Journal of Antimicrobial Chemotherapy 36, 1021-30.
8. Sanchez, C., Armengol, R., Lite, J., Mir, I. & Garau, J. (1992). Penicillin-resistant pneumococci in community-acquired pneumonia. Lancet 339, 988.
9. Moreno, S., Garcia-Leoni, M. E., Cercenado, E., Diaz, M. D., Bernaldo de Quiros, J. C. L. & Bouza, E. (1995). Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clinical Infectious Diseases 20, 1195-200.
10. Dagan, R., Abramson, O., Leibovitz, E., Lang, R., Goshen, S., Greenberg, D. et al. (1996). Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Paediatric Infectious Diseases Journal 15, 980-5.
11. Friedland, I. R. & Klugman, K. P. (1992). Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 339, 405-8.
12. Bradley, J. S. & Connor, J. D. (1991). Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to β-lactam antibiotics. Paediatric Infectious Diseases Journal 10, 871-3.
13. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing: 6th Informational Supplement. NCCLS Document M100-N6, Vol. 15, no. 14. NCCLS, Villanova, PA.
14. Dalhoff, A., Fischer, E., Heidtmann, M. & Hesse, D. (1996). In-vitro activity of Bay 12-8039, a new 8-methoxyquinolone. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-002, p. 100. American Society for Microbiology, Washington, DC.
15. Bauernfeind, A. & Jungwirth, R. (1996). In-vitro activity of Bay 12-8039, a novel 8-methoxyquinolone, in comparison with ciprofloxacin. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-003, p. 100. American Society for Microbiology, Washington, DC.
16. Herrington, J. A., Federici, J. A., Painter, B. G., Remy, J. M., Barbiero, M. L. & Thurberg, B. E. (1996). In-vitro activity of Bay 12-8039, a new 8-methoxyquinolone. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F004, p. 100. American Society for Microbiology, Washington, DC.
17. Vissali, M. A., Jacobs, M. R. & Applebaum, P. C. (1996). Antipneumococcal activity of Bay 12-8039, a new 8-methoxyquinolone, compared to three other quinolones and five β-lactams. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-006, p. 101. American Society Microbiology, Washington, DC.
18. Thomson, K. S., Backes, S. S. & Sanders, C. C. (1996). Susceptibility to Bay 12-8039 of pneumococci and staphylococci with varying levels of ciprofloxacin resistance. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents & Chemotherapy, New Orleans, LA, 1996. Abstract F-016, p. 102. American Society for Microbiology, Washington, DC.
19. Georgopoulos, A., Buxbaum, A. & Graninger, W. (1996). Activity of Bay 12-8039 against 1154 clinical isolates of Streptococcus pneumoniae. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents & Chemotherapy, New Orleans, LA, 1996. Abstract F-005, p. 100. American Society for Microbiology, Washington, DC.
20. Felmingham, D., Robbins, M. J., Leakey, A., Salman, H., Dencer, C., Clark, S., Ridgeway, G. L. & Gruneberg, R. N. (1996). In-vitro activity of Bay 12-8039 against bacterial respiratory tract pathogens, mycoplasmas, and obligate anaerobic bacteria. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-008, p. 101. American Society for Microbiology, Washington, DC.
21. Wise, R., Andrews, J. M. & Brenwald, N. (1996). In-vitro activity of Bay 12-8039, a new 8-methoxyquinolone, in comparison with other fluoroquinolones and beta-lactams against recent isolates and chlamydias. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-010, p. 101. American Society for Microbiology, Washington, DC.
22. Kitzis, M. D., Goldstein, F. W., Miegi, M. & Acar, J. F. (1996) In-vitro activity of Bay 12-8039 against multiply-resistant Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecalis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-012, p. 102. American Society for Microbiology, Washington, DC.
23. Visalli, M. A., Jacobs, M. R. & Applebaum, P. C. (1996). MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrobial Agents and Chemotherapy 40, 362-6.
24. Nau, R., Schmidt, T., Kaye, K., Froula, J. L. & Tauber, M. G. (1995). Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy 39, 593-7.
25. Stass, H. H., Dalhoff, A., Kubitza, D. & Rahr, G. (1996). Bay 12-8039, a new 8-methoxyquinolone: first pharmacokinetic results in healthy male volunteers. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-024, p. 104. American Society for Microbiology, Washington, DC.
26. Pan, X. S. & Fisher, L. M. (1996). Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. Journal of Bacteriology 178, 4060-9.
27. Munoz, R. & De la Campa, A. G. (1996). parC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrobial Agents and Chemotherapy 40, 2252-7.
28. Janoir, C., Zeller, V., Kitzis, M. D., Moreau, N. J. & Gutmann, L. (1996). High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrobial Agents and Chemotherapy 40, 2760-4.
29. Tankovic, J., Perichon, B., Duval, J. & Courvalin, P. (1996). Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrobial Agents and Chemotherapy 40, 2505-10.